Total sales from drugs, medical devices, insurance premiums, and healthcare services. Up 3.90% from last year. Management has guided capital spending of $1.8 billion to $2.0 billion.

What remains after subtracting all operating costs — salaries, materials, rent, R&D — from revenue. This is the profit from actually running the business, before interest and taxes. Operating margin is 17.4%, meaning 17 cents of every dollar of revenue becomes operating profit.

The bottom line — what the company actually earned after all expenses, interest, and taxes. This is the number that gets divided by shares outstanding to calculate earnings per share (EPS), which directly affects the stock price. Net margin is 15.0%. Note: results include non-recurring items (restructuring and other costs, including severance, impairments of long-lived assets, and disposition of a consolidated joint venture ($362 million), cost of revenues adjustments, including accelerated depreciation and inventory revaluation ($64 million)) that may not repeat.

Operating cash flow minus capital expenditure. This is the money available for dividends, share buybacks, debt repayment, or acquisitions. Free cash flow is what many professional investors consider the truest measure of financial health.

Earnings per share — net income divided by total shares outstanding (including stock options and convertible bonds that could become shares). This is the single number most investors watch because it directly connects company profits to your ownership stake.

Cash paid to shareholders each year for every share they own. Healthcare dividends are often funded by patent-protected drug revenue with predictable cash flows.

Everything the company owns — cash, factories, equipment, patents, inventory, investments. Includes drug patents, manufacturing facilities, clinical trial data, and acquired pharmaceutical portfolios.

Money available right now — bank accounts, money market funds, short-term government bonds. This is the company's financial cushion. More cash means more flexibility to invest, acquire, or survive a downturn without borrowing.

All money the company owes — bonds, bank loans, credit facilities. Compare this to cash to understand the net debt position. The company holds $9,852 million in cash against this debt.

Total number of shares that exist — owned by all investors, insiders, and institutions combined. When the company reports EPS, this is the denominator. Share buybacks reduce this number, which increases EPS even without earnings growth.

How much debt the company uses for every dollar of shareholder equity. Under 100% means more equity than debt (conservative). Over 200% means heavy leverage. Banks and utilities naturally run higher ratios.

Actual cash generated from running the business — not accounting profits, real money coming in the door. This is more trustworthy than net income because it's harder to manipulate. A company can report profits but still run out of cash.

Money spent on long-term assets — manufacturing plants, research labs, and clinical trial infrastructure. This is the cost of maintaining and growing the business. Management has guided $1.8 billion to $2.0 billion for capital spending.

Operating cash flow minus capital expenditure. This is the money available for dividends, share buybacks, debt repayment, or acquisitions. Free cash flow is what many professional investors consider the truest measure of a company's financial health.

A non-cash expense that spreads the cost of pharmaceutical manufacturing equipment and acquired drug patents over their useful life. This reduces reported income but no cash actually leaves the company — that's why it gets added back to calculate EBITDA and operating cash flow.

Measures how well reported earnings match actual cash generation. HIGH means earnings are backed by real cash. LOW means the company may be using accounting techniques to inflate reported numbers. Professional investors check this before trusting EPS.

42% of revenue comes from repeat sources — ongoing contracts, subscriptions, or regular customer purchasing patterns rather than one-time sales. Higher recurring revenue means more predictable future earnings.

Operating cash flow divided by net income. Above 1.0x means the company generates more cash than it reports in profits — a sign of high-quality earnings. At 1.2x, the company is converting reported profits to cash efficiently.

One-time items that affect the bottom line but won't repeat: restructuring and other costs, including severance, impairments of long-lived assets, and disposition of a consolidated joint venture ($362 million), cost of revenues adjustments, including accelerated depreciation and inventory revaluation ($64 million), selling, general and administrative expenses adjustments, including transaction/integration costs and changes in contingent acquisition consideration ($207 million), pension plan settlement charges ($8 million). When evaluating the company's true earning power, investors strip these out to see what the business earns on a normal basis.

How management sounds in their SEC filings — are they confident, cautious, or defensive? This is analyzed from the actual language used in the 10-K annual report. A shift in tone from prior years can signal changing conditions before the numbers reflect it.

The company's growth is impacted by market declines, cyclicality, and general economic conditions, including inflationary pressures. Risk trend: increasing. This is the single biggest threat to the company's future earnings as identified in their SEC filing.